Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Inks Novel Bioterror-Research Pact With Aerospace Giant, War Expert

NEW YORK, March 11 - Cepheid is joining forces with defense giant Northrop Grumman and Environmental Technologies Group, a subsidiary of a UK aerospace firm, to adapt PCR-based pathogen detectors for use with US Postal Service mail sorting systems, the companies said on Monday.

 

Though the companies do not have a contract with the postal service, they are anticipating future demand: The postal service recently said that it was evaluating PCR technology that may soon be used to detect potential bioterror agents within its mail systems.

 

The partnership involves Northrop's Automation and Information Systems Division, which supplies equipment to the USPS. Northrop Grumman is a major defense contractor with the US government. It also develops radar, navigation systems, precision weapons, space systems, and electronic-warfare technology.

 

Financial terms of the agreement were not disclosed.

 

Environmental Technologies Group, a subsidiary of London-based Smiths, develops detectors for biological, chemical, and nuclear warfare agents. It is based in Baltimore, Md.

 

The two companies have a contract with the Department of Defense to develop handheld biological agent detection machines, and Cepheid, of Sunnyvale, Calif., is working to create portable DNA detection devices.

In December, the company granted ETG a nonexclusive sublicense on several patents for analytical-reaction technology that permits rapid DNA analysis of bioterrorism agents in portable devices.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.